Isaac Dean

9PUBLICATIONS
70CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Medical mycologyMechanobiologyTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Mar 03, 2026
Effects of oncolytic immunotherapy with RP1 (vusolimogene oderparepvec) on immune cells mediate responsiveness to anti-PD-1 via STING-mediated interferon signaling.

Victoria Roulstone, Joan Kyula, Elizabeth Appleton

|Jul 15, 2025
Author Correction: Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasion.

Victoria Roulstone, Joan Kyula-Currie, James Wright

|Jun 16, 2025
In Vivo Labeling Resolves Distinct Temporal, Spatial, and Functional Properties of Tumor Macrophages and Identifies Subset-Specific Effects of PD-L1 Blockade.

Colin Y C Lee, Isaac Dean, Nathan Richoz

|May 24, 2025
Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasion.

Victoria Roulstone, Joan Kyula-Currie, James Wright

|Oct 11, 2024
Type-H endothelial cell protein Clec14a orchestrates osteoblast activity during trabecular bone formation and patterning.

Georgiana Neag, Jonathan Lewis, Jason D Turner

|Jan 24, 2024
Tumour-retained activated CCR7+ dendritic cells are heterogeneous and regulate local anti-tumour cytolytic activity.

Colin Y C Lee, Bethany C Kennedy, Nathan Richoz

Pageof 2

Frequent Collaborators

5 joint publications

David R Withers

4 joint publications

Scott A Hammond

4 joint publications

Bethany Kennedy

4 joint publications

Menna R Clatworthy